Carbon Biosciences, a Longwood Fund founded biotech company developing parvovirus-derived gene therapies, has launched with $38 million of financing led by Agent Capital.
Agent is joined by Longwood Fund, Astellas Venture Management LLC, the Cystic Fibrosis Foundation, Solasta Ventures, University of Tokyo Innovation Platform (UTokyoIPC), and Camford Capital.
Massachusetts-based Carbon is harnessing novel parvovirus vectors that can deliver larger gene therapy payloads with enhanced tissue specificity and with minimal neutralizing immunity and the potential to re-dose.
The company plans to use the series A funding to advance the development of its programs for genetic diseases, initially building on the research of scientific co-founders John F. Engelhardt, director, Center for Gene Therapy at the University of Iowa, and Robert M. Kotin, Professor of Microbiology and Physiological Systems at the University of Massachusetts Chan Medical School.
Cystic Fibrosis Foundation agreement
“Carbon’s platform has the potential to expand the role of gene therapy in treating some of the world’s most devastating and difficult to treat diseases,” said Joel Schneider, president and CEO of Carbon Biosciences.
“Our vision is to enable a new generation of genetic medicines with differentiated vectors that have the potential to address the immunological, targeting and payload limitations inherent in current viral and non-viral delivery technologies.
“As the first jointly funded program launched under a collaborative agreement between the Cystic Fibrosis Foundation and Longwood Fund, we are motivated by the potential impact our research may have in significantly improving care for cystic fibrosis patients.”
“Identifying vectors that can effectively deliver therapeutics to target tissues, such as the lung, has been a major challenge in realizing the full potential of gene therapy,” said Geeta Vemuri, managing partner and founder of Agent Capital.
“We believe that Carbon’s proprietary platform can address this challenge by leveraging novel vectors from the broader parvovirus family to deliver optimal payloads to specific tissues. Carbon’s technology will enable a diversified pipeline with potential applications across the wide range of tissues impacted in many unaddressed diseases.”
“Carbon’s novel platform addresses key challenges with AAV and non-viral based therapies. Our lead program is the first gene therapy program demonstrating tissue tropism to the lung with the capacity to deliver the full length CFTR gene and an appropriate promotor,” Engelhardt said.
“Preliminary pre-clinical data as well as studies on human populations suggest wide applicability of our lead clinical candidate and the potential to re-dose patients.”